An investigation on behalf of investors in NASDAQ:CMRX shares over potential wrongdoing at Chimerix was announced and NASDAQ:CMRX stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/15/2016 -- An investigation for shareholders of Chimerix Inc (NASDAQ:CMRX) was announced over potential breaches of fiduciary duties by certain directors at Chimerix.
Investors who purchased shares of Chimerix Inc (NASDAQ:CMRX) have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Chimerix directors breached their fiduciary duties and caused damage to the company and its shareholders.
On December 28, 2015, Chimerix Inc announced that its Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint for the prevention of clinically significant cytomegalovirus (CMV) infection through Week 24 after transplant. Shares of Chimerix Inc (NASDAQ:CMRX) declined from $35.82 per share on December 24, 2015, to as low as $6.51 per share on December 28, 2015.
On March 11, 2016, NASDAQ:CMRX shares closed at $5.39 per share.
Those who purchased shares of Chimerix Inc (NASDAQ:CMRX) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego